The alterations of serum nitric oxide levels in diabetic retinopathy

Naciye Kurtul; Hülya Aksoy; Sadrettin Pençe; Ebubekir Bakan; Orhan Baykal

doi:10.58600/eurjther.2001-12-1-1422-arch

Authors

Naciye Kurtul Kahramanmaraş Sütçü İmam Üniversitesi Fen-Edebiyat Fakültesi, Kimya Bölümü, Kahramanmaraş
Hülya Aksoy Atatürk Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Erzurum
Sadrettin Pençe Gaziantep Üniversitesi Tıp Fakültesi Fizyoloji Anabilim Dalı, Gaziantep
Ebubekir Bakan Atatürk Üniversitesi Tıp Fakültesi, Biyokimya Anabilim Dalı, Erzurum
Orhan Baykal Atatürk Üniversitesi Tıp Fakültesi Göz Hastalıkları Anabilim Dalı, Erzurum

DOI:

https://doi.org/10.58600/eurjther.2001-12-1-1422-arch

Keywords:

Diabetes mellitus, nitric oxide, retinopathy

Abstract

Diabetic retinopathy (DR) is one of the major complications of diabetes mellitus. Despite intensive research effort the pathogenic mechanisms important to the initation and progression of DR are stili poorly understood. Endothelial dysfunction has been implicated in the pathogenesis of DR. Nitric oxide (NO) is a potent vasodilator released by endothelial cells that may play an important role in modulating the vascular tone. in this study, serum NO level in samples obtained from Type il diabetic patients with retinopathy was measured spectrophotometricly. Thirtytwo patients that were included in the study, were grouped with respect to the degree of retinopathy. An association between serum NO level of the patients and the degree of retinopaty was sought. The serum NO Ievel in patients with diabetic retinopathy was signifıcantly decreased compare to control group. For this reason it is concluded !hat this change in serum level of NO may have a role in pathophysiology of diabetic retinopathy.

Metrics

Metrics Loading ...

References

Calver A, Collier J, Vallance P. lnhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulindependent diabetes. J Clin Invest. 1992; 90:2548- 2554.

Kiff RJ, Gardiner SM, Compton AM, Bennett T. The effects of endothelin-1 and N°-nitro L-arginine methyl ester on regional haemodynamics in consciousrats with streptozotocin-induced diabetes mellitus. Br J Pharmacol 1991;103:1321-1326.

Komers R, Ailen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes. D iabetes 1994; 4 3: 1190-1 1 97.

Lawrence E, Brain SD. Altered microvascular reactivity to endothelin-1, endothelin-3 and NG-nitro L-arginine methyl ester in streptozotocin-induced diabetes mellitus. Br J Pharmacol 1992; l 06: 1035- 1040

Moncada S, Radomski MW, Palmer RMJ. Endothelium derived relaxing factor: identifıcation as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988; 37:2495-2501.

Nathan C. Nitric oxide as asecretory product of mammalian cells. Faseb J 1992; 6:3051-3064.

Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from Larginine. Nature 1988; 333:664-666.

Wang ZY, Hakanson R. Role of nitric oxide (Nü) in ocular inflammation. Br J Pharmacol 1995; 116: 2447-2450.

Gardiner SM, Compton AM, Bennet T, Palmer RMJ, Moncada A. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 1990; 15:486-492.

Goldstein IM, Ostwald P, Roth S. Nitric oxide: a review of its role in retina! function and disease. Vision Res 1996;36( 18):2979-2994.

MacAllister RJ, Vallance P. The L-arginine: Nitric oxide pathway in the human cardiovascular system. JIFCC 1996; 8:152-158.

Anggard E. Nitric oxide: mediator, murderer and medicine. Lancet 1994; 343: 1199-1206.

Hattat N. Diabet retinopatisinin etyopato-genezi. Oftalmoloji 1993; 2(1): 13-15.

MacGregor LC, Rosecan LR, Laties AM, Matschinsky FM. Altered retina! metabolism in diabetes. The J Biol Chem 1986; 261(9): 4046-4051.

MüftUoğlu G. Retinanın damar hastalıkları. In Özkan Ş, Pazarlı H, Oğuz V, Akar S, (eds) Göz hastalıkları. İstanbul, İst. Üniv. Tıp Fak. Yay, 1997: 291-297.

American Diabetes Association. Diabetic retinopathy. Diabetes care 1998; 21 (1): 157-59.

Klein R. Retinopathy and other ocular complications in diabetes. in: Porte D, Sherwin RS (eds) Ellenberg and Rifkin's Diabetes Mellitus. (5th ed) Stamford, Appleton and Lange, 1997; 931-969.

Mallet B, Vialettes B, Haroche S, Escoffıer P. Stabilization of severe proliferative diabetic retinpathy by long term treatmant with SMS 201-995. Diabetes and Metabolism 1992; 18:438-444.

Ulbig MRW, Hamilton AMP. Factors İnfluencing the naturel history of diabetic retinopathy. Eye 1993; 7:242-249.

Damcı T, Oşar Z. Diabet komplikasyon-larının önlenmesi ve tedavisi. Türk Diabet Yıllığı 1996-97 1997; 12:249-253.

Ghirlanda G, Leo ASD, Caputo S, Cercone S, Greco AV. From functional to microvascular abnormalities in early diabetic retinopathy. Diabetes/Metabolism Rev 1997; 13:15-35.

Klein R, Klein BEK. Diabetic Eye disease. Lancet 1997; 350:197-204.

Sözen T. Diabetes mellitusun dejeneratif komplikasyonları. In: Gedik O. Akalın S, (eds) Diabetes Mellitus Ankara, Güneş Kitabevi, 1989: 93- 138.

Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo study. Br Med J 1992; 304: 19-22.

McCarty MF. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathypreventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Med Hypotheses 1998; 50(5):435-449.

Rand 1. Recent advances in diabetic retinopathy. Anı J Med 1981; 70: 595-602.

Arısoy İ. Diabetik anjiopati ve tedavisi. Türk Diabet Yıllığı. İstanbul, Nurettin Uycan Basım San., 1984: 93-111.

Juvenil diabetes foundation international countdown: retinopathy. Search Progress Report 1988; 9: 16-18.

Kanski JJ. Retina! vascular disorders. Clin Ophthalmolgy Butterworths 1984; 344-369.

Addison DJ, Garner A, Ashton N. The degeneration of intramural pericytes in diabetic retinopathy. Br Med J, 1970; !: 264-266.

Deussen A, Sonntag M, Vogel R. L-argininederived nitric oxide: A major determinant of uveal blood flow. Experimental Eye Research 1993; 57:127-134.

Toda N, Kitamura Y, Okamura T. Role of nitroxidegic nerve in dog retinal arterioles in vivo and arteries in vitro. American Journal of Physiology 1994; 266: 1985-1992.

Tilton RG, Chang K, Hasan KS. Prevention of diabetic vascular dysfunction by guanidines: Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 1993; 42:221-232.

Schmetterer L, Findl O, Fasching P, Ferber W, Strenn K, Breiteneder H, Adam H, Eichler HG, Woltz M. Nitric oxide and ocular blood flow in patients with IDDM. Diabetes 1997; 46:653-658.

Champe PC, Harvey RA. Biyokimya, Lippincott's Mustared Review serısı (2.baskı) (Çev.Tokullugil A, Dirican M, Ulukaya E.). İstanbul, Nobel Tıp Kitabevi 1997; 25-111.

Nathan DG, Oski FA. Human hemoglobins; normal and abnormal methemoglobinemia. in Bunn HF (ed) Hematoloji of infancy and childhood {41h ed) Philadelphia, WB Saunders, 1993; 6:1-30.

Lukens JN, Lee GR. The abnormal hemoglobins. ln Lee GR, Bithell CT, Foerster J, Athens JW, Lukens JN (eds) Wintrobe's Clinical Henıatology (91h ed). Pennsylvania, Lee and Febiger, 1993; 1006- 1053.

Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one-step assay with nitrate reductase. Clin Chem 1995; 4(6):904-907.

Carlos AP, Philip R. Hypertension in diabetes mellitus. Endcrinology and Metabolism Clinics of North America 1996; 25(2):421-423.

Cari A. A multicenter study: United King-dom Prospective Diabetes Study. Hypertension 1985; 7: 118.

Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Eng J Med , 1993; 329:2002-2012.

Raij L. Nitric oxide and the kidney. Circulation 1993; 87[V]: 26-29.

Kubes P, Suzuki M, Granger ON. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci 1991; 88:4651-4655.

Yılmaz G, Esser P, Kociek N, Aydın P, Heiman K. Elevated vitreous nitric oxide levels in patients with proliferative diabetic retinopathy. Anı J Ophthalnıol 2000; 130: 87-90.

Elabbady AA, Gagnon C, Hassouna MM. Diabetes mellitus increase Nü synthase in penises but not in major pelvic ganglia of rats. B J Urol 1995; 76: 196-202.

Kolb H, Kolb BV. Nitric oxide: A pathogenic factor in autoimmunity. Imnıunol Tod 1992; 13:157- 161.

Luscher TF, Richard V. Interaction between endothel derivating Nü and SIN-! İn hunıan and porchine blood vessels. J Cardiovasc Pharmacol 1990; 14:67-80.

Hattori Y, Kawasaki H, Abe K. Super oxide disnıutase recovers altered endotheliunı-dependent relaxationin diabetic rat. Anı J Physiol 1991; 261: 1086-1091.

Corbett JA, Mc Daniel ML. Nitric oxide nıediated autoinımune destruction of beta celi? Possible therapeutic interventions in IDDM. Diabetes USA 1992; 41(8):899-903.

Panagiotidis G, Alnı P, Lundquist I. Inhibition of islet NO syntase increases arginine-induced insulin release. Eur J Pharmacol 1992; 229:277-281.